ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $16.32, moving +2.06% from the previous trading session.
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
Adma Biologics (ADMA) closed at $15.59 in the latest trading session, marking a -4.24% move from the prior day.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $17.5, denoting a +1.16% move from the preceding trading day.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $17.59, signifying a +1.62% move from its prior day's close.
ADMA Biologics: Business Update And My Price Target
ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider buying, and a poison pill signaled management's confidence in profitability.
Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Adma Biologics (ADMA) closed at $17.7, marking a -1.28% move from the previous day.
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
